- 1,256
- 2,105
- Joined
- Mar 26, 2013
Big 3 for play for me
Msft
Jumia
Upwork
Msft
Jumia
Upwork
OFFICIAL STOCK MARKET AND ECONOMY THREAD VOL. A NEW CHAPTER
- Thread in 'General' Thread starter Started by johnnyredstorm,
- Start date
- 57,356
- 60,722
- Joined
- Aug 6, 2012
Ive had Jumia on my watchlist for like 2 months now. Can’t believe I didn’t pull the trigger.
- 37,755
- 39,889
- Joined
- Jan 18, 2006
Hadn't heard of Jumia. Nice jump today though.
- 1,256
- 2,105
- Joined
- Mar 26, 2013
Biggest e-commerce in Africa.
Potentially meli /baba type of play.
Holding really long.. They need a good ER.
Added BA calls 205 aug 21.
- 37,755
- 39,889
- Joined
- Jan 18, 2006
I have been avoiding anything aviation. You think BA is going to rally?
- 1,256
- 2,105
- Joined
- Mar 26, 2013
Current holdings... Still watching and looking around for some plays.
- 1,256
- 2,105
- Joined
- Mar 26, 2013
I work in aviation. So may be a bit bias but yes..
Also due to the fact its been dropping. Someone somehwere will take a position and pump.
- 28,527
- 17,016
- Joined
- Mar 22, 2003
I’ve pumped and dumped BA 5 times since March. Easy money
- 74,630
- 24,046
- Joined
- Apr 4, 2008
Trimmed a little FSLY today. Will let the rest run to 150 and 200 before selling.
- 2,599
- 2,593
- Joined
- Jul 29, 2012
Sold my CRM 200 Sep CRM calls just now (wtih CRM at $201).
Bought it at the dip as well from 2 weeks ago. Looks like it was hitting the resistance of the ascending channel it was on. Had to take profits.
So from the dip 2 weeks back, I bought and sold TWLO, PYPL, and CRM montly calls. I was hoping to play TWLO and CRM through their earnings, but my price target for them was reached already. So I had to execute.
Bought it at the dip as well from 2 weeks ago. Looks like it was hitting the resistance of the ascending channel it was on. Had to take profits.
So from the dip 2 weeks back, I bought and sold TWLO, PYPL, and CRM montly calls. I was hoping to play TWLO and CRM through their earnings, but my price target for them was reached already. So I had to execute.
- 12,038
- 14,850
- Joined
- Jul 27, 2013
- 29,691
- 20,955
- Joined
- Dec 23, 2009
PTON spiking into earnings. Does somebody know something most people don't?
- 34,439
- 26,010
- Joined
- Jul 13, 2005
Yes. To never sell a white girl stock early.
- 29,691
- 20,955
- Joined
- Dec 23, 2009
Always bet on Becky
- 74,630
- 24,046
- Joined
- Apr 4, 2008
Becky got me interested in opening up a Shopify site selling Becky goods 
- 28,527
- 17,016
- Joined
- Mar 22, 2003
Becky got me interested in opening up a Shopify site selling Becky goods
It’s the reason ETSY has been en fuego - their purchase power can’t be denied
- 29,691
- 20,955
- Joined
- Dec 23, 2009
Covid masks and dog sweaters. Make them matching designs and holy ****, you'll have a $20B valued company IPO'ing next year. Becky fueling revenues through the damb roof.Becky got me interested in opening up a Shopify site selling Becky goods
- 21,312
- 11,950
- Joined
- Oct 10, 2005
$ROKU and thread favorite, $FSLY, next Wednesday.
FSLY looking good for Wednesday. Should have pulled the trigger on the $105 call for 08/07 that I was watching on Friday, but I didn’t want to hold over the weekend
.
- 12,038
- 14,850
- Joined
- Jul 27, 2013
$COCP
*Finally Running
NEWS RELEASE 3-AUG-2020
New published study from K-State virologists identifies potential COVID-19 treatment
KANSAS STATE UNIVERSITY
MANHATTAN, KANSAS -- Yunjeong Kim and Kyeong-Ok "KC" Chang, virologists in the College of Veterinary Medicine at Kansas State University, have published a study showing a possible therapeutic treatment for COVID-19.
Pathogenic coronaviruses are a major threat to global public health, as shown by severe acute respiratory syndrome coronavirus, or SARS-CoV; Middle East respiratory syndrome coronavirus, known as MERS-CoV; and the newly emerged SARS-CoV-2, the virus that causes COVID-19 infection.
The study, "3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice," appears in the Aug. 3 issue of the prestigious medical journal Science Translational Medicine. It reveals how small molecule protease inhibitors show potency against human coronaviruses. These coronavirus 3C-like proteases, known as 3CLpro, are strong therapeutic targets because they play vital roles in coronavirus replication.
"Vaccine developments and treatments are the biggest targets in COVID-19 research, and treatment is really key," said Chang, professor of diagnostic medicine and pathobiology. "This paper describes protease inhibitors targeting coronavirus 3CLpro, which is a well-known therapeutic target."
The study demonstrates that this series of optimized coronavirus 3CLpro inhibitors blocked replication of the human coronaviruses MERS-CoV and SARS-CoV-2 in cultured cells and in a mouse model for MERS. These findings suggest that this series of compounds should be investigated further as a potential therapeutic for human coronavirus infection.
Chang and Kim have been using National Institutes of Health grants to develop antiviral drugs to treat MERS and human norovirus infections. Their work extends to other human viruses such as rhinoviruses and SARS-CoV-2.
"The work that this group of collaborators has been doing on antivirals and inhibitors for SARS and MERS at K-State for a number of years has been vital to their ability to quickly pivot to emphasize research on SARS-CoV-2 virus and therapeutics," said Peter K. Dorhout, vice president for research at K-State.
Co-collaborators on the research include teams lead by Bill Groutas at Wichita State University, Stanley Perlman at the University of Iowa and Scott Lovell at the University of Kansas.
"Drs. Groutas, Perlman and Lovell brought decades of experience to our research team," Chang said. "We would not have been able to come this far without important collaborations with our colleagues at other institutions."
Getting things published right now is very important for the scientific community," Kim said. "I think we are adding valuable information to the antiviral field."
The new compounds in the publication are exclusively licensed and being developed by Cocrystal Pharma for COVID-19. K-State Innovations Partners handles commercial technology licensing for the university.
*Finally Running
| Kansas State University | News and Communications Services
www.k-state.edu
NEWS RELEASE 3-AUG-2020
New published study from K-State virologists identifies potential COVID-19 treatment
KANSAS STATE UNIVERSITY
MANHATTAN, KANSAS -- Yunjeong Kim and Kyeong-Ok "KC" Chang, virologists in the College of Veterinary Medicine at Kansas State University, have published a study showing a possible therapeutic treatment for COVID-19.
Pathogenic coronaviruses are a major threat to global public health, as shown by severe acute respiratory syndrome coronavirus, or SARS-CoV; Middle East respiratory syndrome coronavirus, known as MERS-CoV; and the newly emerged SARS-CoV-2, the virus that causes COVID-19 infection.
The study, "3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice," appears in the Aug. 3 issue of the prestigious medical journal Science Translational Medicine. It reveals how small molecule protease inhibitors show potency against human coronaviruses. These coronavirus 3C-like proteases, known as 3CLpro, are strong therapeutic targets because they play vital roles in coronavirus replication.
"Vaccine developments and treatments are the biggest targets in COVID-19 research, and treatment is really key," said Chang, professor of diagnostic medicine and pathobiology. "This paper describes protease inhibitors targeting coronavirus 3CLpro, which is a well-known therapeutic target."
The study demonstrates that this series of optimized coronavirus 3CLpro inhibitors blocked replication of the human coronaviruses MERS-CoV and SARS-CoV-2 in cultured cells and in a mouse model for MERS. These findings suggest that this series of compounds should be investigated further as a potential therapeutic for human coronavirus infection.
Chang and Kim have been using National Institutes of Health grants to develop antiviral drugs to treat MERS and human norovirus infections. Their work extends to other human viruses such as rhinoviruses and SARS-CoV-2.
"The work that this group of collaborators has been doing on antivirals and inhibitors for SARS and MERS at K-State for a number of years has been vital to their ability to quickly pivot to emphasize research on SARS-CoV-2 virus and therapeutics," said Peter K. Dorhout, vice president for research at K-State.
Co-collaborators on the research include teams lead by Bill Groutas at Wichita State University, Stanley Perlman at the University of Iowa and Scott Lovell at the University of Kansas.
"Drs. Groutas, Perlman and Lovell brought decades of experience to our research team," Chang said. "We would not have been able to come this far without important collaborations with our colleagues at other institutions."
Getting things published right now is very important for the scientific community," Kim said. "I think we are adding valuable information to the antiviral field."
###
The new compounds in the publication are exclusively licensed and being developed by Cocrystal Pharma for COVID-19. K-State Innovations Partners handles commercial technology licensing for the university.
Last edited:
- 94,106
- 33,146
- Joined
- Oct 24, 2010
anyone got a pretty straight forward video on options? any help would be appreciated
- 1,256
- 2,105
- Joined
- Mar 26, 2013
Pushing a 25k gains over the week. Blessed.
- 1,905
- 539
- Joined
- Sep 29, 2012
any kodak bag holders in the thread 
- 12,038
- 14,850
- Joined
- Jul 27, 2013
- 577
- 589
- Joined
- Feb 19, 2019
Anyone buying FSLY into earnings?
- 37,755
- 39,889
- Joined
- Jan 18, 2006
I think that train left the station.
Similar threads
